Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
77
VTVT Quote, Financials, Valuation and Earnings
Last price:
$37.18
Seasonality move
:
20.36%
Day range:
$36.09 - $37.99
52-week range:
$13.15 - $37.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15,335.63x
P/B ratio:
2.09x
Volume:
17.5K
Avg. volume:
13.9K
1-year change:
170.37%
Market cap:
$147.7M
Revenue:
$1M
EPS (TTM):
-$3.32
Analysts' Opinion
-
Consensus RatingvTv Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $40.67, vTv Therapeutics, Inc. has an estimated upside of 8.45% from its current price of $37.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $37.50.
Fair Value
-
According to the consensus of 3 analysts, vTv Therapeutics, Inc. has 8.45% upside to fair value with a price target of $40.67 per share.
VTVT vs. S&P 500
-
Over the past 5 trading days, vTv Therapeutics, Inc. has overperformed the S&P 500 by 4.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
vTv Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
vTv Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter vTv Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
vTv Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter vTv Therapeutics, Inc. reported earnings per share of -$1.08.
Enterprise value:
49.5M
EV / Invested capital:
0.70x
Price / LTM sales:
15,335.63x
EV / EBIT:
--
EV / Revenue:
2,913.59x
PEG ratio (5yr expected):
-0.29x
EV / Free cash flow:
-2.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$19K
Return On Assets:
-59.27%
Net Income Margin (TTM):
-166935.29%
Return On Equity:
-124.41%
Return On Invested Capital:
-123.38%
Operating Margin:
-28776.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $9K | $1M | $17K | -- | -- | |
| Gross Profit | -$81K | $910K | -$19K | -$22K | -$2K | |
| Operating Income | -$27.1M | -$24M | -$29.8M | -$6.5M | -$10.7M | |
| EBITDA | -$27M | -$23.9M | -$29.8M | -$6.5M | -$10.7M | |
| Diluted EPS | -$10.56 | -$4.53 | -$3.32 | -$0.88 | -$1.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.2M | $28.8M | $10.1M | $43M | $99.5M | |
| Total Assets | $31.4M | $39.5M | $14.9M | $43.2M | $99.5M | |
| Current Liabilities | $5.5M | $7.5M | $10.3M | $6.4M | $10.2M | |
| Total Liabilities | $8.4M | $27.9M | $29.4M | $25.3M | $29M | |
| Total Equity | $23.1M | $11.6M | -$14.5M | $17.9M | $70.5M | |
| Total Debt | $1.2M | $890K | $686K | $32K | $328K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.5M | -$23.4M | -$20.4M | -$6.4M | -$4.8M | |
| Cash From Investing | -- | $4.4M | -- | -- | -- | |
| Cash From Financing | $15.4M | $52.3M | $77.4M | $2.5M | $77.4M | |
| Free Cash Flow | -$22.5M | -$23.4M | -$20.4M | -$6.4M | -$4.8M | |
VTVT
Sector
Market Cap
$147.7M
$28.1M
Price % of 52-Week High
98.71%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-84.29%
-1.49%
1-Year Price Total Return
170.37%
-17.13%
Beta (5-Year)
0.505
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$35.35
200-day SMA
Buy
Level
$20.43
Bollinger Bands (100)
Buy
Level
17.05 - 29.39
Chaikin Money Flow
Sell
Level
-3.9K
20-day SMA
Buy
Level
$31.25
Relative Strength Index (RSI14)
Buy
Level
72.23
ADX Line
Buy
Level
18.96
Williams %R
Sell
Level
-4.0788
50-day SMA
Buy
Level
$27.56
MACD (12, 26)
Buy
Level
8.96
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
88.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.0888)
Sell
CA Score
(Annual)
Level (-8.3316)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.5103)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
Stock Forecast FAQ
In the current month, VTVT has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VTVT average analyst price target in the past 3 months is $40.67.
-
Where Will vTv Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that vTv Therapeutics, Inc. share price will rise to $40.67 per share over the next 12 months.
-
What Do Analysts Say About vTv Therapeutics, Inc.?
Analysts are divided on their view about vTv Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that vTv Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $35.00.
-
What Is vTv Therapeutics, Inc.'s Price Target?
The price target for vTv Therapeutics, Inc. over the next 1-year time period is forecast to be $40.67 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VTVT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for vTv Therapeutics, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VTVT?
You can purchase shares of vTv Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase vTv Therapeutics, Inc. shares.
-
What Is The vTv Therapeutics, Inc. Share Price Today?
vTv Therapeutics, Inc. was last trading at $37.18 per share. This represents the most recent stock quote for vTv Therapeutics, Inc.. Yesterday, vTv Therapeutics, Inc. closed at $37.50 per share.
-
How To Buy vTv Therapeutics, Inc. Stock Online?
In order to purchase vTv Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VTVT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VTVT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.29x
-0.01x
P/B ratio
2.09x
1.81x
Price / LTM sales
15,335.63x
1.59x
Growth Metrics
VTVT
Sector
Revenue growth
--
4.62%
Earnings growth
-23.17%
11.06%
Revenue (5-year growth)
-18.12%
6.5%
Earnings forecast
-$0.98
-$0.21
Profitability
VTVT
Sector
Profitability FY 2024
$928K
$3.6M
Return on invested capital
-123.38%
-31.84%
Return on assets
-59.27%
-27.96%
Return on equity
-124.41%
-37.63%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
24
Estimated Next Earnings Date
Mar
25
Balance Sheet
VTVT
Sector
Total cash
$98.5M
$26.4M
Short term investments
--
$25.7M
Total assets
$38.3M
$76.9M
Long term debt
$328K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
